Statistical Design and Considerations of a Phase 3 Basket Trial for Simultaneous Investigation of Multiple Tumor Types in One Study
Authors:
- 2 July 2016
- journal article
- research article
- Published by Taylor & Francis in Statistics in Biopharmaceutical Research
- Vol. 8 (3) , 248-257
Abstract
The discovery of numerous molecular subtypes of common cancers leads to the investigation of biomarkers potentially predictive of treatment effect of an experimental treatment in multiple histologies. However, the prevalence of a putative predictive biomarker within a histology is often low, which makes it challenging to enroll adequate number of patients in a conventional histology-based confirmatory trial. An alternative approach is to study patients with a common biomarker signature in a “basket” trial across multiple histologies. This study design has previously been used to explore experimental therapies with potentially transformative effects. We present a general design concept of a Phase 3 basket trial broadly applicable to any effective therapy. The trial is designed with scientific and statistical rigor to enable the approval of an experimental treatment in multiple tumor indications based on the outcome from a single study. Given the difficulty in indication selection, the basic idea is to prune the inactive indications at an interim analysis and pool the active indications in the final analysis. A critical statistical issue of the basket design is Type I error control for the pooled analysis after pruning. While pruning may be seen as cherry-picking which tends to inflate the Type I error, it also shares similarity with a binding futility analysis which tends to deflate the Type I error if all indications are pruned. The net impact of pruning is complicated. The use of different endpoints for pruning and pooling further complicates the issue. This paper will provide statistical details on Type I error control for the general basket design concept under three sample size adjustment strategies after pruning. Power and sample size calculations are also provided. Comparisons are made to a straightforward design without pruning. Supplementary materials for this article are available online.Keywords
This publication has 21 references indexed in Scilit:
- Maximizing Return on Socioeconomic Investment in Phase II Proof-of-Concept TrialsClinical Cancer Research, 2014
- Bayesian hierarchical modeling of patient subpopulations: Efficient designs of Phase II oncology clinical trialsClinical Trials, 2013
- Evaluation of Early Efficacy Endpoints for Proof-of-Concept TrialsJournal of Biopharmaceutical Statistics, 2013
- Integrating predictive biomarkers and classifiers into oncology clinical development programmesNature Reviews Drug Discovery, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- The BATTLE Trial: Personalizing Therapy for Lung CancerCancer Discovery, 2011
- Selection and bias—Two hostile brothersStatistics in Medicine, 2009
- I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant ChemotherapyClinical Pharmacology & Therapeutics, 2009
- Optimal Cost-Effective Go-No Go Decisions in Late-Stage Oncology Drug DevelopmentStatistics in Biopharmaceutical Research, 2009
- Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine KinasesClinical Cancer Research, 2008